| Bioactivity | Pro8-Oxytocin TFA is a a modified oxytocin (OXT) ligand. Pro8-Oxytocin produces more potent and efficacious responses at primate OXTR and stronger behavioral effects than the consensus mammalian OXT ligand (Leu8-Oxytocin). Pro8-Oxytocin TFA produce a less efficacious response than Vasopressin (HY-B1811) (AVP) at human AVPR1a and higher efficacious response than AVP at marmoset AVPR1a[1]. |
| Name | Pro8-Oxytocin TFA |
| Sequence | Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Pro-Gly-NH2 (Disulfide bridge: Cys1-Cys6) |
| Shortening | CYIQNCPPG-NH2 (Disulfide bridge: Cys1-Cys6) |
| Formula | C42H62N12O12S2.xC2HF3O2 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mustoe A, et al. Leu8 and Pro8 oxytocin agonism differs across human, macaque, and marmoset vasopressin 1a receptors. Sci Rep. 2019 Oct 29;9(1):15480. |
Pro8-Oxytocin TFA
CAS: F: C42H62N12O12S2.xC2HF3O2 W:
Pro8-Oxytocin TFA is a a modified oxytocin (OXT) ligand. Pro8-Oxytocin produces more potent and efficacious responses at
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.